SOLVD


Also found in: Acronyms.

SOLVD

Cardiology A series of clinical trials–Studies of Left Ventricular Dysfunction that evaluated the effect of antihypertensives–eg, with enalapril, an ACE inhibitor, on M&M in Pts with CHF. See ACE inhibitor, Congestive heart failure Consensus II, Enalapril.
References in periodicals archive ?
Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry.
Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry.
The best data come from the Studies of Left Ventricular Dysfunction (SOLVD) trial (N.
In 1991, the Studies of Left Ventricular Dysfunction (SOLVD) trial (8) demonstrated a 26% risk reduction for death or hospitalization due to heart failure (95% confidence interval [CI], 18-34) for those treated with the ACE inhibitor enalapril (Vasotec)(LOE: 1).
Michael Bohm of the University of Saarland in Homburg/Saar, Germany, observed that the new Val-HeFT finding of sharply increased mortality in CHF patients with new-onset AF echoes earlier data from the Studies of Left Ventricular Dysfunction (SOLVD) trial, which also demonstrated that AF worsens prognosis.
Authors, year CNH assay (Ref.) Study protocol (method) Benedict et al., A subset of 241 patients ANP (RIA) 1996 (87) with asymptomatic left ventricular dysfunction were enrolled in the SOLVD Prevention Trial Tsutamoto et al., 290 consecutive patients ANP (IRMA) 1999 (88) with asymptomatic or BNP (IRMA) minimally and newly symptomatic left ventricular dysfunction (functional classes I-II; mean left ventricular EF, 37%) were studied Stanek et al., 91 patients with HF NT-proANP (ELISA) 2001 (89) (left ventricular EF NT-proBNP (ELISA) <25%) receiving 40 mg/day BNP (RIA) enalapril and double- blind atenolol (50-100 mg/day) or placebo were enrolled Anand et al., Plasma BNP was measured BNP (IRMA) 2003 (90) before randomization and during follow-up in ~4300 patients (the Valsartan HF Trial).
(7.) Shindler DM, Kostis JB, Yusus S, Quinones MA, Pitt B, Stewart D, et al, Diabetes mellitus, a predictor of morbidity and mortality inthe Studies of Left Ventricular Dysfunction (SOLVD) Trials andRegistry.
One large retrospective study evaluated 6796 patients using potassium-sparing diuretics vs non-potassium-sparing diuretics in the Studies of Left Ventricular Dysfunction (SOLVD) trial.
Particularly noteworthy was a retrospective analysis of data from the land-mark Studies of Left Ventricular Dysfunction (SOLVD) and second Valsartan Heart Failure Trial (Val-HeFT II).
"ACE inhibitors were demonstrated unequivocally to be lifesaving in patients with heart failure in 1993 with the SOLVD trial.
Studies of Left Ventricular Dysfunction (SOLVD) ve The Second Perspective Randomised study of Ibopamine on Mortality and Efficacy (PRIME-II) calipmalarinda bazal bobrek fonksiyonlanndaki bozuklugun mortalite icin onemli bir risk faktoru oldugu gosterilmistir (24, 25).
"I think from the evidence that's accumulating, going back to SAVE [the Survival and Ventricular Enlargement trial], SOLVD [Studies of Left Ventricular Dys-function], HOPE, and now EUROPA, it would appear that we're dealing with a class effect," said the cardiologist, who wasn't involved in EUROPA.